-
2024-515830-34-00
5
2023-02-14
Congenital antithrombin deficiency
-
2024-520006-19-00
6
2021-12-15
Non-muscle invasive bladder cancer
-
2024-511686-11-00
5
2021-10-05
Multiple Sclerosis in pediatric patients
-
2024-518195-31-00
6
2021-09-29
acute myocardial infarction
-
2023-510509-17-00
7
2020-06-17
Relapsed and/or refractory Acute Myeloid Leukemia
-
2025-523510-87-00
5
2026-06-25
Obesity
-
2025-523486-17-00
5
2026-06-16
Obesity
-
2025-523396-38-00
9
2026-05-29
Relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r high
-
2025-522093-36-00
10
2026-05-20
Cancer cachexia
-
2024-516551-41-00
4
2026-03-06
Patients with HER2-expressing solid tumors
-
2025-522701-38-00
6
2026-02-26
SUBRETINAL HYPERREFLECTIVE MATERIAL
-
2024-511362-37-00
5
2026-02-18
Non squamous non-small cell lung cancer (NSCLC)
-
2025-522151-26-00
5
2026-02-06
Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growt
-
2025-521043-20-00
10
2026-01-27
Neuroendocrine tumors
-
2024-515658-26-00
5
2026-01-21
Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
-
2025-522026-13-00
4
2026-01-12
Obsessive compulsive disorder
-
2024-512298-28-00
11
2025-12-18
Neovascular age-related macular degeneration
-
2024-519836-18-00
5
2025-12-16
treatment-resistant schizophrenia (TRS)
-
2024-513586-39-00
5
2025-12-10
Prostate Cancer
-
2024-518969-98-00
5
2025-11-04
Neurotrophic Keratopathy
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2024-517232-22-00
5
2025-09-26
KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorect
-
2024-511989-36-00
5
2025-09-24
Ewing Sarcoma
-
2024-520210-21-00
5
2025-09-19
Crohn’s Disease